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Background and Objectives. von Willebrand's disease
(vWD) is a bleeding disorder with variable clinical expres-
sion. Our aim was to classify patients with vWD and to
determine the phenotype in their relatives. 
Design and Methods. The types and subtypes, blood
group frequency and its relevance, bleeding sites,
response to the desmopressin (DDAVP) test, transfusion
requirements and clinical features in type 1 and 2A fam-
ilies were determined in 1,885 patients.
Results. Our findings were: type 1: 91%, type 2A: 3.1%,
severe vWD: 1.3%; type 2N: 1.6%; type low intraplatelet:
2.7%; combined 1+2N: 0.3%. Blood group O prevalence
was 70.5%. Bleeding and transfusion requirements were
not correlated to blood groups. The most frequent symp-
toms were: ecchymoses-hematomas and epistaxis and,
in females over 13 years, also menorrhagia. Normal lev-
els of factor VIII:C were found in 38.4% of the patients.
DDAVP was infused in 567 patients with a good response
in 80.6%. About 9% of our patients needed transfusion
therapy. The diagnosis of von Willebrand’s disease is
more likely in subjects belonging to families with type
2A disease than in members of families with type 1 vWD
in spite of these being symptomatic.
Interpretation and Conclusions. These observations pro-
vide a good strategy to identify, classify and treat vWD
patients without performing molecular assays.
©2001, Ferrata Storti Foundation
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Von Willebrand's disease (vWD) is a life-long bleed-ing disorder that appears to be inherited in anirregular fashion as an autosomal dominant trait,
although a recessive pattern has also been described.1–3
Clinical expression is variable and is characterized by
mucocutaneous hemorrhages (epistaxis, ecchymoses,
easy bruising), with a special constellation of symptoms
in females (menorrhagia, bleeding after vaginal deliv-
ery or Cesarean section). Patients may have a mild,
moderate or severe bleeding tendency from early child-
hood depending on the severity of the von Willebrand
factor (vWF) or factor VIII (FVIII:C) defect.4 vWD is
caused by a quantitative or qualitative defect of vWF,
a high molecular weight glycoprotein that plays a role
in the early phases of hemostasis by promoting platelet
adhesion to the subendothelium5,6 and platelet aggre-
gation under high shear conditions.7 Furthermore, vWF
is crucial in the intrinsic pathway of coagulation since
it is also the carrier of FVIII:C in plasma.4,8 vWD has
been subdivided into three categories which reflect
their physiopathology. Type 1 and 3 vWD refer to par-
tial or virtually complete deficiency of vWF while type
2 vWD refers to a qualitative deficiency. The revised
classification introduced in 1994 by Sadler9 suggested
subdividing type 2 vWD into 4 variants (2A, 2B, 2M,
2N) according to specific details of the phenotype.
Recently, Lethagen10 reported that a substantial num-
ber of patients, formerly assigned to type 1, whose cir-
culating vWF contains mutant subunits in addition to
a quantitative reduction, should be reclassified as type
2. He suggested that some of these patients would be
helped by desmopressin (DDAVP) treatment. Moreover,
Castaman11 described a lack of association between
genotypes, bleeding history and ristocetin cofactor
activity (vWF:RCo) in many families diagnosed as hav-
ing mild type 1 vWD. It is known that normal individu-
als with the 0 blood group have lower levels of FVIII:C
and/or vWF:Ag12-14 than those with a non-0 blood
group. Although the reasons are uncertain, the physio-
logic basis for this difference is most likely related to
differences in the type or amount of vWF glycosyla-
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tion,15 leading to a shortened plasma survival.16 There-
fore, the in vitro characterization of vWD does not offer
a guide to treatment. Our aim was to analyze vWD
patients with a clear personal or family history of bleed-
ing associated with low vWF:RCo levels, and to deter-
mine the phenotype expression in their relatives and
their response to DDAVP.
Design and Methods
Subjects
We analyzed the prevalence of vWD in 2,339 individ-
uals referred to our Department from 1982 to July 1999
because of a personal and/or family history of hemor-
rhages or abnormal pre-surgery clotting assays. In those
individuals with normal plasma FVIII:C, vWF:Ag and
vWF:RCo levels but with a prolonged bleeding time (BT)
or low platelet retention to glass beads (PR) and a per-
sonal or family history of bleeding, intraplatelet vWF:Ag
(i-vWF:Ag) was also assayed. The age and position in
the family were established for each person. Exclusion
criteria were pregnancy, infectious or inflammatory dis-
eases and estrogen-containing contraceptive pill use.
The criteria used to define vWD were intentionally
restrictive in order to avoid overdiagnosis. In all cases,
without considering ABO groups, vWF activity was
below 50 U/dL with the exception of subjects with vWD
types 2N and low intraplatelet in whom the plasma
vWF:RCo and vWF:Ag levels were normal. Type 2A vari-
ant was defined in those patients with reduced
vWF:RCo, normal or slightly reduced levels of vWF:Ag
and absence of large multimers of vWF. Probable type
Normandy (2N) variant was suspected when FVIII:C lev-
el and the FVIII:C binding capacity/vWF:Ag ratio were
low. Combined 1+2N cases were diagnosed in patients
with proportionately low vWF:Ag and vWF:RCo but with
disproportionately low levels of FVIII:C and low FVIII:C
binding capacity/vWF:Ag ratio. Severe vWD was defined
as occurring in those patients with vWF:Ag and
vWF:RCo below 10 U/dL. Low intraplatelet with normal
plasma vWF variant17,18 was defined as occurring in
those patients with only low intraplatelet vWF content.
Platelet content of fibrinogen was also measured to
exclude the presence of platelet abnormalities such as
a low content of α-granules by platelet activation.
Bleeding symptoms and family history of hemorrhages
were obtained by a detailed questionnaire. Specific
symptoms investigated included: epistaxis, menorrhagia,
ecchymoses, hemorrhages (after tooth extraction,
surgery, post-partum), hematomas, hemarthrosis and
hematuria. Each symptom was recorded only when suf-
ficiently fully reported. Laboratory investigation was
offered to all available members of the families. The
blood group was required from each subject. When the
first study was normal and the personal or famiy histo-
ry of bleeding was strong, the studies were repeated at
least 3 times. Intake of any antiplatelet drugs for 10
days before the study was avoided. There were no cas-
es of consanguinity in any of the families. 
Laboratory investigations 
Blood samples. Blood was taken by venipuncture
between 7:30 and 9:00 a.m. after the subjects had been
resting for at least 30 min. Blood was collected in
polypropylene tubes with 0.11 M trisodium citrate (1:10
v:v) for coagulation tests and FVIII:C binding capacity
and 0.11 M trisodium citrate, 50 mM EDTA, 60 mM n-
ethylmaleimide, 2,000 KIU/mL aprotinin (1:10 v:v) for
vWF:Ag, vWF:RCo, and multimeric pattern assays. For
the assays of platelet retention to glass beads, 53.7 mM
EDTA was used as anticoagulant. The samples were cen-
trifuged at 2,000 × g for 15 min. Platelet-poor plasma
was transferred to another tube and centrifuged at
3,000 × g for 30 min. It was then aliquoted and frozen
at –70°C until analyzed.
Phenotypic analysis and laboratory assays. BT was
tested by the Ivy19,20 or Mielke21 method (with a com-
mercial device: Simplate R, General Diagnostics, Morris
Plains, NJ, USA). For the Ivy method, our normal value
was up to 4.30 min, and for the Mielke method, the nor-
mal value was up to 9.30 min. The tests were stopped
when profuse bleeding was still observed at 9 and 18
min, respectively. PR was assayed according to the
Hellem II method22 (normal value: 26-70%). Activated
partial thromboplastin time (APTT)23 was measured by
using rabbit cephalin-kaolin (normal value: 34-50 sec).
FVIII:C was assayed using a one-stage method (normal
value: 50-150 U/dL).24 vWF:Ag was measured by a quan-
titative immunoelectrophoresis technique as described
elsewhere25 (normal value: 50-150 U/dL). vWF:RCo was
measured by the modified method of Macfarlane26 (nor-
mal value: 50-150 U/dL). The multimeric pattern of vWF
was analyzed as described elsewhere.27 FVIII:C binding
capacity was measured by polyclonal anti-vWF capture
of patient vWF on polystyrene tubes with recombinant
FVIII:C. Bound FVIII:C was measured using the chro-
mogenic method. A ratio of bound FVIII:C/vWF:Ag over
0.8 was considered as normal.28,29 i-vWF:Ag (normal
value: 0.1-0.4 U/109 platelets) and i-fibrinogen (normal
value: 30-90 µg/109 platelets) were assayed in the
supernatant of frozen and thawed-washed platelets.
Standard plasma. The local standard plasma used for
the different assays was made by pooling the plasmas
from 20 healthy donors, from a single sample in citrate-
n-ethylmaleimide-EDTA-aprotinin as anticoagulant and
stored at –70°C until analyzed. APTT and FVIII:C were
assayed in each donor. Plasmas with FVIII:C less than 80
U/dL and more than 110 U/dL were discarded. The stan-
dard pool was calibrated for FVIII:C, vWF:Ag and
vWF:RCo activity against the International Reference
Preparation for Factor VIII:C Related Activities in Plas-
ma (IRP) (87/718), National Institute for Biological Stan-
dards and Control, London, UK.
DDAVP infusion 
DDAVP was infused intravenously into 567 patients
over a period of 20 min at a dose of 0.3 µg/kg body wt,
in saline solution. Blood samples were obtained for PR,
APTT, FVIII:C, vWF:Ag, vWF:RCo assays before and 1, 2
Diagnosis of von Willebrand’s disease
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and 24 hours after DDAVP infusion. BT was also mea-
sured. A good response implied that all abnormal para-
meters reached normal levels. The response was inade-
quate if neither FVIII:C nor vWF reached plasma levels
required for hemostasis (>50 U/dL) or if neither BT nor PR
reached normal values. No response meant that all the
parameters remained abnormal or FVIII:C did not reach
plasma levels required for hemostasis (>50 U/dL).
Statistical analysis
Normal ranges for FVIII:C, vWF:Ag and vWF:RCo
(mean values ± 2 standard deviations) were calculated
according to standard proceedures. We performed the
mean-test using the EPI 6.04 from the CDC of Atlanta
(USA). Comparison of the means of the data was per-
formed using a repeated one-way analysis of variance
followed by Student’s t-test for unpaired data. Proba-
bility values less than p<0.05 were considered statisti-
cally significant. The chi-squared test was used to com-
pare the different prevalences.
Results
From the total population of 2,339 individuals stud-
ied, we diagnosed vWD in 1,885, with a predominance
of females (60.6%) The majority of the patients (71.1%)
were over 13 years old. In children below 2 years of age,
the percentage of males with vWD was higher than that
of females (94.5%) (p=0.00001) but over 13 years the
percentage of females rose to 68.7% (p=0.00009). The
classification of vWD patients, according to the labora-
tory tests, is shown in Table 1.
There were 126 patients (6.7%) with only abnormal
laboratory findings of vWD without personal bleeding
manifestations or a family history. These patients con-
sulted us because of abnormal pre-surgical findings. The
prevalences of family and personal symptoms are shown
in Table 1. Low values of PR were observed in 80% of
our patients, while low levels of FVIII:C were found in
only 61.6% (patients with 2N and combined 1+2N vari-
ants were not considered); low vWF:Ag and prolonged
BT were found in 62.2% and 58.4%, respectively. The
distribution of patients according to blood groups was:
70.5% had group 0, 24.8% had group A, 4.1% had group
B and 0.6% had group AB. 
The frequency of clinical symptoms is shown in Table
2. Ecchymoses-hematomas and epistaxis were the most
common clinical symptoms. Considering the age of the
patients, menorrhagia was the second most frequent
clinical symptom in females over 13 years old. Hemo-
philia B and vWD was found in 22 patients. Storage pool
deficiency was diagnosed in 27 patients, whereas abnor-
mal platelet release reaction was diagnosed in 100,
Ehlers Danlos in 6, Noonan syndrome in 4 and Rendu
Osler disease in 2 patients.
Patients with type 1 variant
Type 1 vWD was diagnosed in 1,714 patients, with a
high prevalence in females (Table 1); 87.3% had bleed-
ing symptoms and 70% had blood group O. Laboratory
test results according to blood groups are shown in Table
3. vWF:Ag was significantly lower in group O than in
non-O (p=0.005). FVIII:C levels were slightly lower in
the patients with blood group O (p=0.08). There were no
differences in vWF:RCo, BT and PR between patients
with  O and non-O blood groups, although more patients
with blood group O had low PR than did patients with
a non-O group (83.3% vs 76.9%; p=0.019).
Patients with a diagnosis of 2A, 2N, severe,
“low intraplatelet” or combined 1+2N vari-
ants
Type 2A vWD was diagnosed in 59 patients, with a
similar distribution in males and females (Table1). Bleed-
ing symptoms were present in 90.6% of these patients
and 76% had blood group O. Prolonged BT and low PR
were found in 88.7% and 86.3% of these patients,
respectively. Results were: vWF:RCo: 9.4±12.6 U/dL;
vWF:Ag: 55.6±26.4 U/dL; FVIII:C: 43.2±18.9 U/dL.
Type 2N vWD was functionally diagnosed in 31
patients, with a high prevalence in males (Table 1). All
patients had clinical symptoms and only 59% had group
0 blood. Prolonged BT and low PR were found in 16%
and 53.3% of the patients, respectively. Results were:
FVIII:C: 19.7±19.4 U/dL; vWF:Ag: 97.13±39.1 U/dL;
vWF:RCo: 85.09±31.3 U/dL. The ratio of bound FVIII:C/
vWF:Ag was 0.49±0.238.
Table 1. Incidence of the variants of vWD in our patients.
Overall Males Females With Family 
symptoms history
Type of vWD n % n  % n % % %
Overall 1885 100 743 39.4 1142 60.6 87.7 56.9
1 1714 91 666 38.9 1048 61.1 87.3 55.1
2A 59 3.1 30 50.8 29 49.2 90.6 78.8
2N 31 1.6 22 70.9 9 29.1 100 73.3
Severe 24 1.3 6 25.0 18 75.0 100 73.7
Low intraplatelet 51 2.7 14 27.5 37 72.5 88.2 71.4
Combined 1+ 2N 6 0.3 5 83.3 1 16.6 100 100
Table 2. Frequency of clinical symptoms in vWD patients.
Clinical symptoms Overall Males Females  total  >13 yr
% % % %
Ecchymoses-hematomas 50.4 48.7 51.3 51.4
Epistaxis 38.1 41.7 36.9 35.6
Menorrhagia – – – 47.0
Gingival bleeding 26.1 22.8 28.1 29.1
Bleeding after tooth extraction 28.6 25.3 30.6 33.9
Bleeding after surgery 19.5 16.5 21.5 25
Post-partum hemorrhage – – – 12.9
Hemarthrosis 6.3 15.2 0.9 0.4
Hematuria 4.7 8.4 3.1 1.5
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Severe vWD was diagnosed in 24 patients, with a
high prevalence in females (Table 1). All patients had
bleeding symptoms, only 62.5% had blood group O. Pro-
longed BT and low PR were found in 100% and 95.7%,
respectively. Results were: FVIII:C: 22.5±15.1 U/dL;
vWF:Ag: 2.5±3.7 U/dL; vWF:RCo: 1.1±0.8 U/dL.
Type low intraplatelet with normal plasma vWF vari-
ant was diagnosed in 51 patients, with a high prevalence
in females (Table 1). Eighty-eight percent of these
patients had bleeding symptoms and 58.7% had blood
group O. Prolonged BT and low PR were found in 36.2%
and 90.2%, respectively. Results were: i-vWF:Ag: 0.068±
0.018 U/109 platelets; i-fibrinogen: 52±20 µg/109
platelets; FVIII:C: 62.9±21.5 U/dL; vWF:RCo: 76.9±25.5
U/dL; vWF:Ag: 88.2±27.1 U/dL.
Combined 1+2N vWD was diagnosed in 6 patients (5
males); all had bleeding symptoms and 66.6% had blood
group O. Prolonged BT and low PR were found in all
these patients. Results were: FVIII:C: 10.7±8.6 U/dL;
vWF:RCo: 40.28±6.39 U/dL; vWF:Ag: 45.43±10.5 U/dL.
Analysis of patients with increasing num-
ber of bleeding sites
We evaluated the percentage of patients according to
the number of bleeding sites. There was a high preva-
lence of females with 3 or more bleeding sites. Never-
theless, the incidence of obstetric-gynecologic bleed-
ing was independent of the number of bleeding sites.
The prevalence of blood group O was the same in
patients with no bleeding and in those with one or more
bleeding sites (67.6% vs 69.9%). 
Requirement of replacement therapy
The requirements of replacement therapy were eval-
uated (those patients with associated hemophilia B were
not considered); only 176 (9.3%) patients needed trans-
fusion; 109 patients were males and 67 females
(p=0.000). The most frequent hemorrhagic episodes that
required replacement therapy were: hemarthrosis (knee:
50; ankle: 30; elbow: 27; shoulder: 7; hip: 6; feet: 6),
intramuscular bleeding (thigh: 34; psoas: 14; calf mus-
cles: 13; arm-forearm: 8; buttocks: 7; knee: 5), bleeding
after tooth extraction: 30, epistaxis: 32, bleeding after
surgery: 22, menorrhagia: 16 and post-partum hemor-
rhages: 9. The prevalence of blood group O was 70.4%
in transfused patients vs 68.2% in those not needing
transfusion (p=0.6525). As shown in Table 4, vWF:RCo
and FVIII:C were significantly lower in transfused
patients. Furthermore, there were more patients with
prolonged BT among those requiring transfusions
(p=0.0152). Considering each variant individually, the
requirements of transfusion therapy in our patients were
as follows: 29.1% of patients with severe vWD, 33.3%
with combined phenotype 1+2N, 22% of patients with
type 2A, 10.1% of patients with type 1 disease; 8.8% of
patients with type 2N vWD and 1.9% of those with low
intraplatelet variant. Factor VIII:C concentrates were
used in 104 episodes, cryoprecipitates in 48, plasma in
12, DDAVP in 12 and red blood cells in 45. Twenty-six
patients were transfused but the blood component used
was not identified. DDAVP had been previously tested in
56 of the patients with transfusional requirements: 31
with good response, 23 with inadequate response and
3 with no response.
Responses to DDAVP infusion 
The responses to DDAVP infusion were evaluated in
567 patients. Their ages at the time of receiving the
infusion were from 2 to 5 years (9 patients), 6 to 10
years (41 patients), 11 to 20 years (197 patients), 21 to
40 years (230 patients), and older than 41 years (90
patients). A good response was present in 457/567
patients (80.6%); the high prevalence of females with-
in this group was significant (89.8% vs 65.2%; p=
0.000). The response was inadequate in 91/567 patients
(16%) and 19/567 patients (3.4%) had no response. A
good response was achieved in 84.6% of patients with
type 1 vWD; an inadequate response was found in
54.5% and 31.6% of patients with type 2 A and low
Table 3. Laboratory tests in patients with type 1 vWD con-
sidering the blood groups.
Blood group vWF:RCo vWF:Ag FVIII:C Pts with PR
U/dL U/dL U/dL prolonged patients
BT mean %  low 
values
O  n: 714 × 38.2 45.7 43.9 13.0
SD 11.5 22.3 22.4 46.4% 13.3 83.3%
Non-O n: 288 × 39.0 50.4 46.9 13.2
SD 13.7 27.4 30.1 46.1% 14.1 76.9%
p O vs non-O 0.349 0.005 0.080 0.985 0.815 0.019
X: mean; SD: standard deviation; vWF.RCo: ristocetin cofactor activity; vWF:Ag: von
Willebrand antigen; BT: bleeding time, the percentage of patients with prolonged 
values is given; PR: platelet retention, the mean and SD and also the percentage
of patients with low values are given.
Table 4. Laboratory tests in patients with and without trans-
fusion requirements.
Patients vWF:RCo vWF:Ag FVIII:C Pts. with PR Pts.
U/dL U/dL U/dL prolonged % group O
BT
Non-transf. × 39.3 51.9 49.2 13.8
(n: 1768) SD 16.6 29.8 23.2 51.2% 14.4 68.2%
Transfused × 33.7 48.8 27.8 13.8
(n: 176) SD 16.4 31.4 23.6 63.5% 14.0 70.4
p transf. vs. non-transf. 0.0000 0.188 0.0000 0.0152 0.405 0.6525
X: mean; SD: standard deviation; vWF.RCo: ristocetin cofactor activity; vWF:Ag: von
Willebrand antigen; BT: bleeding time, the percentage of patients with prolonged 
values is given; PR: platelet retention, expressed as mean and SD and also as per-
centage of patients with low values. Transf.: transfused.
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intraplatelet, respectively. No response occurred in
100% and 66.7% of patients with severe type vWD and
2N, respectively.
Phenotype of affected and unaffected mem-
bers in families with vWD types 1 and 2A
In order to analyze the phenotype expression of
affected and unaffected relatives of our population of
vWD patients, we studied a total of 1,188 relatives
belonging to 410 families; 736 patients were diagnosed
and classified as follows: type 1 vWD: 657 patients; type
2A: 44; type 2N: 27 and type severe: 8. It was not pos-
sible to reach a diagnostic classification in the other
452 members; 430 of them belonged to families affect-
ed by vWD type 1 and 50.3% were symptomatic; 9
members belonged to families with type 2A vWD and
33% had clinical symptoms; 13 members belonged to
type 2N families and 66.7% had symptoms.
We could to study the parents and sisters of only 6
patients with severe vWD; in 2 cases, their mothers were
diagnosed as having vWD type 1; in 2 cases both par-
ents were diagnosed as having type 1 vWD; in one case
the mother was classified as having type 2A; in anoth-
er case the sister also had severe vWD and in the 6th
case the mother only showed prolonged BT. 
In non-diagnosed members, we found that 53% of
the subjects with low PR, 61.4% with low FVIII:C and
59.5% with a prolonged BT were symptomatic. Results
of laboratory tests of relatives and their distribution
according to the type of vWD in the families are shown
in Table 5. PR was the most frequently abnormal test in
non-diagnosed relatives.
Furthermore, with the purpose of analyzing the phe-
notype of the disease in members of families with estab-
lished vWD we selected 8 families (4 with type 1 vWD
and 4 with type 2A vWD) in which it was possible to
study 8 or more members. The number of members with
and without diagnosis in each family, type of vWD in the
affected members and clinical symptoms in non-diag-
nosed members were considered. From a total of 40
members belonging to the type 1 families, vWD was
diagnosed in 30% of them; from the 41 members of
type 2A families, 87.8% of the members were shown to
be affected (Table 6). The frequency of symptomatic
members was similar in both groups of families. We
found that 39.3% of non-diagnosed members belong-
ing to families with type 1 vWD were symptomatic,
whereas none of the non-diagnosed members belong-
ing to families with vWD type 2A was symptomatic.
Discussion
In agreement with other authors,2,14,30-34 type 1 was
the most frequent variant of vWD in our patients. The
prevalence of severe type vWD in our series was similar
to,33 higher than,35 and lower than that reported by oth-
er authors.30,34,36,37 The most frequent symptoms in our
population were ecchymoses-hematomas, epistaxis,
bleeding after tooth extraction and menorrhagia in
females over 13 years. About 56.9% of our patients had
a family history; 87.7% of the patients had bleeding
symptoms. Only 6.7% had neither a personal history nor
a family history of bleeding symptoms. To be consid-
ered as having type 1 vWD, the subject should have
vWF:RCo below the blood group specific normal range,
bleeding symptoms11 and a family history or a causative
mutation.38 However, these criteria are difficult to ful-
fill in many patients. It seems appropiate to make a cat-
egory of possible type 1 vWD if only two criteria are
present: tests compatible with type 1 vWD and either
bleeding history or inheritance.40 In agreement with
Nitu-Whalley,39 we consider that the low levels of
vWF:RCo and personal bleeding history are of prime
importance in the diagnosis and treatment of vWD.
Asymptomatic patients with low values of vWF:RCo
should be regarded with caution, as many of them might
not have had a hemostatic challenge to manifest a
bleeding tendency. In these cases, when the diagnosis of
vWD can neither be confirmed nor excluded and the risk
of bleeding is unknown, empirical treatment is recom-
mended.39,40
Considering the age of patients at the time of admis-
sion, in agreement with other authors14 we found that
Table 5. Laboratory tests in non-diagnosed relatives.
Type of vWD in FVIII:C Patients with PR
the families U/dL pts. with prolonged mean % pts.
low values BT % with low values
1 × 60.7 37.8% 36.5% 23.4 56.3
SD 30.6 20.4
2A × 74.2 22.2% 42.9% 17.4 62.5
SD 31.4 9.4
2N × 44.9 58.3% 44.5% 16.4 66.7%
SD 40.9 13.7
X: mean; SD: standard deviation; FVIII:C was expressed as U/dL and the 
percentage of patients with low levels is also given; BT: bleeding time, the 
percentage of patients with prolonged values is given; PR: platelet retention,
expressed as mean and SD. The percentage of patients with low values is also 
given.
Table 6.  Families with 8 and more members studied, num-
ber of subjects affected and symptomatic relatives.
Type 1 Type 2A
Number of families 4 4
Number of members 40 41
Diagnosed members 12/40 30.0% 36/41 87.8%
with symptoms 5/12 41.6% 30/36  83.3%
Non-diagnosed members 28/40 70% 11/28 39.3%
with symptoms 5/41  12.2% 0/5 0.0%
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94.5% of the children below 2 years were males;
between 3 and 12 years the frequency of males and
females were similar but over 13 years, females were
more frequent. Since patients with type 1 vWD have
minor bleeding episodes, menorrhagia was the reason
for the first clinical consultation and the most frequent
clinical symptom in young females, as indeed previous-
ly reported by other authors.41,42 The prevalence of
females was evident in subjects with type 1, severe and
low intraplatelet variants. Menstruation, post-partum
and obstetric-gynecologic complications explain why
more females than males are symptomatic over 13 years
of age and makes it essential to search for a diagnosis,
including the measurement of intraplatelet vWF when
plasma levels are normal. On the other hand, 70.9% of
our 2N type population were males. This could be
because the vWD 2N phenotype mimics hemophilia A;
thus, many cases of mild hemophilia should be re-eval-
uated.43
It has been described that the mean level of vWF in
normal subjects with blood group O is lower than that
in subjects with non-0 blood groups.2,13,39,44 The reasons
for this are uncertain but it is a source of some ambigu-
ity in diagnosis. Most people with blood group O and
two normal vWF alleles have plasma vWF levels below
the normal range and clinical symptoms of mild vWD.
Some authors suggest that normal ranges of vWF should
be defined separately for O and non-O subjects.2 Other
authors suggest that the use of ABO adjusted ranges for
vWF levels might not be essential for diagnosis and con-
sider that the bleeding history is of prime importance in
clinical diagnosis and treat type 1 vWD patients accord-
ingly.39 We found lower levels of vWF:Ag in type 1 vWD
patients with group 0 compared to in patients with non-
0 blood group. Like other authors,39 we think that
patients with low levels of vWF and clinical symptoms
must be considered as vWD, independently of the ABO
group. Moreover, our patients with group O neither bleed
more frequently nor need more transfusions than those
with other blood groups at matched vWF levels in plas-
ma. Interestingly, 70.5% of our patients have blood
group O whereas the frequency of this group in our nor-
mal population is 50.9%.45 Previous reports on a small
sample of type 1 vWD13,14,39 showed similar results. 
It is important to bear in mind that 71.1% of our
patients were diagnosed over 13 years old; in spite of
being a congenital illness, clinical manifestations of
type 1 vWD are not especially evident in childhood.
The requirements of transfusion in our patients were
very low (9.3%) compared with those reported by oth-
er authors, i.e. only 22.4%46 and 33%47 of patients with
severe vWD had never been transfused. The transfusion
requirements were related not only to the low FVIII:C
and vWF:RCo levels (such as in patients with type 2N
and combined 1+2N variants) but also to the prolonged
BT. It was more frequent in males (p<0.000) but this
can be overestimated considering that the search for
Normandy variant patients is more frequent in suspect-
ed hemophiliacs.
When the number of bleeding sites was considered,
33% of the patients had 3 or more sites of hemorrhages,
with a higher prevalence of females, independently of
obstetric-gynecologic bleeding and transfusion require-
ments. 
In agreement with other authors,48-50 good response
to DDAVP was found in 80.6% of our patients, inade-
quate response in 16% and no response occurred in the
remaining 3.4%. Good response to DDAVP was more
frequent in females. To date, DDAVP is the best and
safest therapy.
We found a large group of patients with bleeding
symptoms, normal levels of plasma vWF:Ag and
vWF:RCo but with low intraplatelet vWF:Ag content as
described first by Weiss.17 A defective release or content
from cellular compartments of vWF was excluded in
these patients by measuring intraplatelet fibrinogen
content. The exact role of platelet vWF has not been
defined although several studies have indicated that it
plays a key role in primary hemostasis48,51,52 and in the
adherence of platelets to the subendothelial surface.53,54
Normal levels of intraplatelet vWF:RCo are associated
with normal BT and decreased clinical bleeding in type
1 vWD48,55 whereas low levels were associated with a
poor response to DDAVP.48 In agreement with Fressin-
aud,54 we found low PR in 90.2% of these patients and
DDAVP infusion did not correct this abnormality. The
above concepts could explain why 31.6% of these
patients have an inadequate response to DDAVP in spite
of having normal plasma vWF levels, unlike patients with
type 1 variant, in whom only 15% have an inadequate
response.
The sensitivity of each of the assays for the diagnosis
of vWD and their predictive values in screening  patients
with hemorrhagic diatheses are at present unknown. It
should be borne in mind that 38.4% of patients show
normal levels of FVIII:C, therefore, the diagnosis of vWD
should not be discarded in patients with clinical symp-
toms but normal FVIII:C. In patients with a diagnosis of
vWD, PR was the most frequently abnormal laboratory
assay (besides vWF:RCo). In spite of normal routine
screening tests, we consider that vWF:RCo, vWF:Ag, PR
and BT should be included among the first level tests for
evaluation of subjects with a mild bleeding diathesis. In
our experience, PR prompts a diagnosis of vWD. We, thus,
recommend its use because it is easy and inexpensive,
although difficult to standardize.
Some authors56 have described a penetrance of 58% in
the classic vWD. We observed a similar phenotype expres-
sion (30%) in the type 1 variant having a lower incidence
of symptomatic members with a diagnosis of vWD, but a
higher phenotype expression in type 2A (87.8%). 
These results indicate the possibility of diagnosing
and treating a substantial group of patients with vWD
even in the absence of molecular information, which is
not always available in the most frequent type of vWD,
the type 1 variant.
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Potential implications for clinical practice
Personal bleeding history and low vWf:RCo are of
prime importance in the diagnosis and treatment of
vWD. Asymptomatic subjects with low vWf:RCo
should be regarded with caution, since many of them
might not have had a hemostatic challenge suffi-
cient to evidence the bleeding tendency. When the
diagnosis of vWD can neither be confirmed nor
excluded, the risk of bleeding is unknown. Patients
with low vWF and clinical symptoms must be con-
sidered as having vWD, independently of the ABO
group. In spite of normal levels of FVIII:C, when
patients have clinical symptoms, the diagnosis of
vWD should not be discarded.
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